Login to Your Account

Theravance, Glaxo Respiratory Drugs Show Phase II Promise

By Randall Osborne

Thursday, December 4, 2003
Less than a year after entering a potential $545 million deal with GlaxoSmithKline plc to find new, long-acting beta2-agonists for respiratory diseases, Theravance Inc. said a pair of early Phase II studies yielded positive results. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription